The Signal
$IOVA Q3 earnings (11/5) locked the narrative flip from clinical risk to manufacturing moat operationalization: $122M revenue, 60% gross margin, $382M cash runway into 2029, EPS swung to -$0.05 (vs. -$0.25 Y/Y). Precision TIL biomarker stratification now validated—soft tissue sarcomas hit 55% ORR, NSCLC KRAS WT cohort entering trial with durability as primary differentiator. sBLA filing imminent on 24.6% ORR second-line + mDOR trajectory. Simultaneously, $AQST operationalizes Anaphylm launch execution post-CRL resolution: NDA resubmission integrated with FDA feedback, PharmFilm manufacturing solves 30-year portability gap vs. EpiPen, pre-PDUFA approval trajectory locks Q1–Q2 2027 catalyst. Biotech-AI intersection operationalizes via biomarker-driven patient stratification and manufacturing moat, not discovery hype. Both plays trade on execution discipline into 2H27.
What's Moving
- $IOVA (precision TIL profitability glide) — Q3 beat validates cash runway into 2029, sBLA filing removes clinical binary on NSCLC, soft tissue sarcomas 55% ORR unlocks 7x melanoma TAM expansion. 150+ ATCs operationalized removes manufacturing ceiling. $20–25M revenue floor into 2H27 sBLA approval path. (via @biotechscanner)
- $AQST (Anaphylm pre-PDUFA + $2B TAM) — NDA resubmission locked post-FDA feedback integration, launch hiring operationalized (Medical Liaisons, Regional Directors hired), PharmFilm portability solves incumbency trap. $473M cap vs. $1.8B post-approval floor = 3.8x upside into 1H27 PDUFA window. (via @biotechscanner)
- Biomarker-driven candidate stratification operationalizes discovery de-risking — RFD4-Proteina (IPD × NVIDIA), ESM3 structural embeddings (CARTnet B-cell epitope prediction), MaskNGly (N-glycosylation site prediction from language models). Models narrow wet-lab candidate pools; no shortcut to Phase 1 but validation cost collapse unlocks smaller biotech entry. (via @biologyaidaily)
Crosscurrents
- Market volatility masks execution strength — $IOVA +$AQST posted best-in-class operational/commercial momentum Nov 3–5 amid Nasdaq -6.4% single-day drop. Near-term technical weakness obscures Q1 2027 catalyst conviction.
- $RVMD valuation hype vs. durability risk — $RVMD Rasonque hit $198M Q3 sales (>5,000 patients in 5 weeks launch), but analyst buyside expectations at $400–500M Q4 imply demand saturation risk + payer pushback on pricing. Contrast: $IOVA durability story offers structural moat $RVMD lacks.
Tradecraft
Desk Notes
- @biotechscanner — Conviction lock on precision TIL profitability + sBLA approval; $IOVA 150+ ATC footprint + $382M cash removes valuation ceilings; Anaphylm pre-PDUFA traction justifies 3.8x upside into 1H27.
- @adamfeuerstein — $RVMD Rasonque commercial velocity unreal (5K+ patients in 5 weeks) but Q4 guidance hype carries payer-adoption risk; FDA safety questions on gene therapy ($NVS SMA gene therapy tumors signal) ripple into TIL durability narratives.
- @biologyaidaily — AlphaFold 3 RNA novelty gap + CARTnet template-guided epitope design narrow early-stage biotech discovery risk pools; ESM2/ESM3 structural embeddings operationalize variant prioritization at omics scale.